SS
IMNM icon

SBI Securities’s Immunome IMNM Stock Holding History

SBI Securities’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212 Sell
10
-6
-38% -$128 ﹤0.01% 3309
2026
Q1 		$350 Buy
16
+7
+78% +$156 ﹤0.01% 3021
2025
Q4 		$193 Sell
9
-14
-61% -$246 ﹤0.01% 3221
2025
Q3 		$269 Sell
23
-47
-67% -$468 ﹤0.01% 3219
2025
Q2 		$651 Buy
70
+20
+40% +$164 ﹤0.01% 2853
2025
Q1 		$337 Buy
50
+26
+108% +$249 ﹤0.01% 3024
2024
Q4 		$255 Buy
+24
New +$290 ﹤0.01% 3156

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

SBI Securities's IMNM Position: Q2 2026 in Review

SBI Securities reduced its Immunome (IMNM) stake by 38% in Q2 2026, selling an estimated $128 and leaving 10 shares worth $212. The position accounts for ﹤0.01% of the portfolio, ranked #3309.

SBI Securities first reported a position in IMNM in Q4 2024 and has held it in 7 quarters since. The position peaked at $651 in Q2 2025. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • SBI Securities held 10 shares of Immunome worth $212 as of Q2 2026.
  • SBI Securities sold 6 Immunome shares in Q2 2026, an estimated $128.
  • Immunome made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3309 holding.
  • SBI Securities first reported a position in Immunome in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Immunome position peaked at $651 in Q2 2025.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.